Download PDF Introduction Facing rising scrutiny from American activist investors, GlaxoSmithKline (GSK), Britain’s second-largest pharmaceutical company, is undertaking a major strategic shift. By spinning off its consumer healthcare division, and recently acquiring Sierra Oncology for $1.9bn, which is about to introduce a new blood cancer treatment to the market, GSK Read more…
Williiams (WMB); market cap (as of 02/10/15): $27.63bn Energy Transfer Equity (ETE); market cap (as of 02/10/15): $21.96bn Introduction On Monday September 28, Energy Transfer Equity (ETE) announced to acquire its rival The Williams Company Inc. (WMB) for c. $37.7bn (assuming $4.6bn of Williams’ debt). This transaction happened in Read more…
Alexion Pharmaceuticals Inc.; market cap (as of 09/05/2015): $32.54bn Synageva Biopharma Corp.; market cap (as of 09/05/2015): $7.91bn Introduction On May 6, 2015, Alexion Pharmaceuticals Inc. (NASDAQ:ALXN), the manufacturer of the world’s single most expensive prescription drug Soliris, and Synageva BioPharma Corp. (NASDAQ:GEVA) have entered into a definitive agreement Read more…